Iovance Biotherapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-391.0M | $-372.2M | $-444.0M | $-395.9M | $-342.3M | $-259.6M | $-197.6M | $-123.6M |
| Depreciation & Amortization | $12.9M | $11.3M | $11.6M | $9.3M | $3.1M | $1.1M | $1.2M | $956.0K |
| Depreciation | — | — | — | $9.3M | $3.1M | $1.1M | $1.2M | $1.0M |
| Amortization | $23.1M | $26.4M | $9.8M | $0 | — | — | — | — |
| Stock-Based Compensation | $61.6M | $109.6M | $62.6M | $84.0M | $69.8M | $40.9M | $24.3M | $20.0M |
| Net Cash from Operating Activities | $-302.4M | $-353.0M | $-361.8M | $-292.8M | $-227.9M | $-205.1M | $-158.9M | $-101.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $33.8M | $11.1M | $22.3M | $20.4M | $37.6M | $46.8M | $6.9M | $1.2M |
| Business Acquisitions | — | — | $212.6M | — | — | — | — | — |
| Net Cash from Investing Activities | $47.5M | $-96.4M | $-155.2M | $256.5M | $132.0K | $-317.9M | $90.0M | $-386.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $300.8M | $390.7M | $463.0M | $190.2M | $239.3M | $576.4M | $6.1M | $424.3M |
| Net Change in Cash | $47.0M | $-59.3M | $-56.8M | $153.8M | $11.5M | — | — | $-63.2M |
| Free Cash Flow | $-336.2M | $-364.0M | $-384.1M | $-313.2M | $-265.5M | $-251.9M | $-165.8M | $-102.4M |